Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 435 entries
Sorted by: Best Match Show Resources per page
Current concepts of rotator cuff tendinopathy.

International journal of sports physical therapy

Factor D, Dale B.
PMID: 24790788
Int J Sports Phys Ther. 2014 Apr;9(2):274-88.

PURPOSE/BACKGROUND: Tendinopathies are a broad topic that can be examined from the lab to their impact upon function. Improved understanding will serve to bring this pathology to the forefront of discussion, whether in the clinic or the classroom. The...

Cite
Factor D, Dale B. Current concepts of rotator cuff tendinopathy. Int J Sports Phys Ther. 2014;9(2):274-88
Factor, D., & Dale, B. (2014). Current concepts of rotator cuff tendinopathy. International journal of sports physical therapy, 9(2), 274-88.
Factor, David, and Dale, Barry. "Current concepts of rotator cuff tendinopathy." International journal of sports physical therapy vol. 9,2 (2014): 274-88.
Factor D, Dale B. Current concepts of rotator cuff tendinopathy. Int J Sports Phys Ther. 2014 Apr;9(2):274-88. PMID: 24790788; PMCID: PMC4004132.
Copy Download .nbib Format: NLM
Developments in the treatment of hemophilia B: focus on emerging gene therapy.

The application of clinical genetics

Cancio MI, Reiss UM, Nathwani AC, Davidoff AM, Gray JT.
PMID: 24159262
Appl Clin Genet. 2013 Oct 18;6:91-101. doi: 10.2147/TACG.S31928.

Hemophilia B is a genetic disorder that is characterized by a deficiency of clotting factor IX (FIX) and excessive bleeding. Advanced understanding of the pathophysiology of the disease has led to the development of improved treatment strategies that aim...

Cite
Cancio MI, Reiss UM, Nathwani AC, et al. Developments in the treatment of hemophilia B: focus on emerging gene therapy. Appl Clin Genet. 2013;6:91-101doi: 10.2147/TACG.S31928.
Cancio, M. I., Reiss, U. M., Nathwani, A. C., Davidoff, A. M., & Gray, J. T. (2013). Developments in the treatment of hemophilia B: focus on emerging gene therapy. The application of clinical genetics, 691-101. https://doi.org/10.2147/TACG.S31928
Cancio, Maria I, et al. "Developments in the treatment of hemophilia B: focus on emerging gene therapy." The application of clinical genetics vol. 6 (2013): 91-101. doi: https://doi.org/10.2147/TACG.S31928
Cancio MI, Reiss UM, Nathwani AC, Davidoff AM, Gray JT. Developments in the treatment of hemophilia B: focus on emerging gene therapy. Appl Clin Genet. 2013 Oct 18;6:91-101. doi: 10.2147/TACG.S31928. PMID: 24159262; PMCID: PMC3805181.
Copy Download .nbib Format: NLM
Puerarin attenuates ovalbumin-induced lung inflammation and hemostatic unbalance in rat asthma model.

Evidence-based complementary and alternative medicine : eCAM

Dong F, Wang C, Duan J, Zhang W, Xiang D, Li M.
PMID: 24523826
Evid Based Complement Alternat Med. 2014;2014:726740. doi: 10.1155/2014/726740. Epub 2014 Jan 02.

Aim. We aimed to investigate and evaluate the preventive activity of puerarin on the ovalbumin-induced asthma rat model. Materials and Methods. Male Wistar rats were sensitized intraperitoneally on days 0, 7, and 14 and challenged to ovalbumin intratracheally on...

Cite
Dong F, Wang C, Duan J, et al. Puerarin attenuates ovalbumin-induced lung inflammation and hemostatic unbalance in rat asthma model. Evid Based Complement Alternat Med. 2014;2014:726740doi: 10.1155/2014/726740.
Dong, F., Wang, C., Duan, J., Zhang, W., Xiang, D., & Li, M. (2014). Puerarin attenuates ovalbumin-induced lung inflammation and hemostatic unbalance in rat asthma model. Evidence-based complementary and alternative medicine : eCAM, 2014726740. https://doi.org/10.1155/2014/726740
Dong, Feng, et al. "Puerarin attenuates ovalbumin-induced lung inflammation and hemostatic unbalance in rat asthma model." Evidence-based complementary and alternative medicine : eCAM vol. 2014 (2014): 726740. doi: https://doi.org/10.1155/2014/726740
Dong F, Wang C, Duan J, Zhang W, Xiang D, Li M. Puerarin attenuates ovalbumin-induced lung inflammation and hemostatic unbalance in rat asthma model. Evid Based Complement Alternat Med. 2014;2014:726740. doi: 10.1155/2014/726740. Epub 2014 Jan 02. PMID: 24523826; PMCID: PMC3910132.
Copy Download .nbib Format: NLM
Evaluation of the plasma quality after filtration.

Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences

Mahmoodian Shooshtari M, Mousavi Hosseini K.
PMID: 22615604
Daru. 2010;18(2):114-7.

BACKGROUND AND THE PURPOSE OF THE STUDY: The quality of some of the human plasma derived drugs such as coagulation factor VIII and coagulation factor IX which can be used for the treatment of hemophilia A and B, depends...

Cite
Mahmoodian Shooshtari M, Mousavi Hosseini K. Evaluation of the plasma quality after filtration. Daru. 2010;18(2):114-7
Mahmoodian Shooshtari, M., & Mousavi Hosseini, K. (2010). Evaluation of the plasma quality after filtration. Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 18(2), 114-7.
Mahmoodian Shooshtari, M, and Mousavi Hosseini, K. "Evaluation of the plasma quality after filtration." Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences vol. 18,2 (2010): 114-7.
Mahmoodian Shooshtari M, Mousavi Hosseini K. Evaluation of the plasma quality after filtration. Daru. 2010;18(2):114-7. PMID: 22615604; PMCID: PMC3304377.
Copy Download .nbib Format: NLM
Morphology of the mouthparts of larval lobsters, homarus americanus (decapoda: nephropidae), with special emphasis on their setae.

The Biological bulletin

Factor JR.
PMID: 20693367
Biol Bull. 1978 Jun;154(3):383-408. doi: 10.2307/1541067.

1. This study provides a detailed account of the morphology of the mouthparts of larval lobsters (Homarus americanus) and the setae they bear. The results describe the types of setae found on the mouthparts, present a scheme for their...

Cite
Factor JR. Morphology of the mouthparts of larval lobsters, homarus americanus (decapoda: nephropidae), with special emphasis on their setae. Biol Bull. 1978;154(3):383-408doi: 10.2307/1541067.
Factor, J. R. (1978). Morphology of the mouthparts of larval lobsters, homarus americanus (decapoda: nephropidae), with special emphasis on their setae. The Biological bulletin, 154(3), 383-408. https://doi.org/10.2307/1541067
Factor, J R. "Morphology of the mouthparts of larval lobsters, homarus americanus (decapoda: nephropidae), with special emphasis on their setae." The Biological bulletin vol. 154,3 (1978): 383-408. doi: https://doi.org/10.2307/1541067
Factor JR. Morphology of the mouthparts of larval lobsters, homarus americanus (decapoda: nephropidae), with special emphasis on their setae. Biol Bull. 1978 Jun;154(3):383-408. doi: 10.2307/1541067. PMID: 20693367.
Copy Download .nbib Format: NLM
Recommended reading from the beth Israel hospital pulmonary and critical care fellowship program: phillip factor, d.o., program director.

American journal of respiratory and critical care medicine

Annan EL, Sharif M, Mathew J, Factor P.
PMID: 21804123
Am J Respir Crit Care Med. 2011 Aug 01;184(3):379-80. doi: 10.1164/rccm.201011-1868RR.

No abstract available.

Cite
Annan EL, Sharif M, Mathew J, et al. Recommended reading from the beth Israel hospital pulmonary and critical care fellowship program: phillip factor, d.o., program director. Am J Respir Crit Care Med. 2011;184(3):379-80doi: 10.1164/rccm.201011-1868RR.
Annan, E. L., Sharif, M., Mathew, J., & Factor, P. (2011). Recommended reading from the beth Israel hospital pulmonary and critical care fellowship program: phillip factor, d.o., program director. American journal of respiratory and critical care medicine, 184(3), 379-80. https://doi.org/10.1164/rccm.201011-1868RR
Annan, Edwin Laryea, et al. "Recommended reading from the beth Israel hospital pulmonary and critical care fellowship program: phillip factor, d.o., program director." American journal of respiratory and critical care medicine vol. 184,3 (2011): 379-80. doi: https://doi.org/10.1164/rccm.201011-1868RR
Annan EL, Sharif M, Mathew J, Factor P. Recommended reading from the beth Israel hospital pulmonary and critical care fellowship program: phillip factor, d.o., program director. Am J Respir Crit Care Med. 2011 Aug 01;184(3):379-80. doi: 10.1164/rccm.201011-1868RR. PMID: 21804123.
Copy Download .nbib Format: NLM
Functions of the Heterologous Intron-Derived Fragments Intra and Extra Factor IX-cDNA Coding Region on the Human Factor IX Expression in HepG2 and Hek-293T Cells.

Iranian journal of biotechnology

Sam MR, Zomorodipour A, Haddad-Mashadrizeh A, Ghorbani M, Kardar GA, Sam S.
PMID: 30805387
Iran J Biotechnol. 2018 May 15;16(2):e1753. doi: 10.21859/ijb.1753. eCollection 2018 May.

BACKGROUND: Human FIX (hFIX) gene transfer into hepatocytes has provided a novel approach for treatment of hemophilia B. To obtain an improved expression of hFIX, the functional OBJECTIVES: We aim to evaluate the functions of the heterologous intron-derived fragments...

Cite
Sam MR, Zomorodipour A, Haddad-Mashadrizeh A, et al. Functions of the Heterologous Intron-Derived Fragments Intra and Extra Factor IX-cDNA Coding Region on the Human Factor IX Expression in HepG2 and Hek-293T Cells. Iran J Biotechnol. 2018;16(2):e1753doi: 10.21859/ijb.1753.
Sam, M. R., Zomorodipour, A., Haddad-Mashadrizeh, A., Ghorbani, M., Kardar, G. A., & Sam, S. (2018). Functions of the Heterologous Intron-Derived Fragments Intra and Extra Factor IX-cDNA Coding Region on the Human Factor IX Expression in HepG2 and Hek-293T Cells. Iranian journal of biotechnology, 16(2), e1753. https://doi.org/10.21859/ijb.1753
Sam, Mohammad Reza, et al. "Functions of the Heterologous Intron-Derived Fragments Intra and Extra Factor IX-cDNA Coding Region on the Human Factor IX Expression in HepG2 and Hek-293T Cells." Iranian journal of biotechnology vol. 16,2 (2018): e1753. doi: https://doi.org/10.21859/ijb.1753
Sam MR, Zomorodipour A, Haddad-Mashadrizeh A, Ghorbani M, Kardar GA, Sam S. Functions of the Heterologous Intron-Derived Fragments Intra and Extra Factor IX-cDNA Coding Region on the Human Factor IX Expression in HepG2 and Hek-293T Cells. Iran J Biotechnol. 2018 May 15;16(2):e1753. doi: 10.21859/ijb.1753. eCollection 2018 May. PMID: 30805387; PMCID: PMC6371630.
Copy Download .nbib Format: NLM
Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy.

Molecular therapy. Methods & clinical development

Samelson-Jones BJ, Arruda VR.
PMID: 30705923
Mol Ther Methods Clin Dev. 2018 Dec 31;12:184-201. doi: 10.1016/j.omtm.2018.12.007. eCollection 2019 Mar 15.

Hemophilia A (HA) and hemophilia B (HB) are X-linked bleeding disorders due to inheritable deficiencies in either coagulation factor VIII (FVIII) or factor IX (FIX), respectively. Recently, gene therapy clinical trials with adeno-associated virus (AAV) vectors and protein-engineered transgenes,...

Cite
Samelson-Jones BJ, Arruda VR. Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy. Mol Ther Methods Clin Dev. 2018;12:184-201doi: 10.1016/j.omtm.2018.12.007.
Samelson-Jones, B. J., & Arruda, V. R. (2019). Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy. Molecular therapy. Methods & clinical development, 12184-201. https://doi.org/10.1016/j.omtm.2018.12.007
Samelson-Jones, Benjamin J, and Arruda, Valder R. "Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy." Molecular therapy. Methods & clinical development vol. 12 (2019): 184-201. doi: https://doi.org/10.1016/j.omtm.2018.12.007
Samelson-Jones BJ, Arruda VR. Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy. Mol Ther Methods Clin Dev. 2018 Dec 31;12:184-201. doi: 10.1016/j.omtm.2018.12.007. eCollection 2019 Mar 15. PMID: 30705923; PMCID: PMC6349562.
Copy Download .nbib Format: NLM
A Highly Productive CHO Cell Line Secreting Human Blood Clotting Factor IX.

Acta naturae

Kovnir SV, Orlova NA, Shakhparonov MI, Skryabin KG, Gabibov AG, Vorobiev II.
PMID: 29713519
Acta Naturae. 2018 Jan-Mar;10(1):51-65.

Hemophilia B patients suffer from an inherited blood-clotting defect and require regular administration of blood-clotting factor IX replacement therapy. Recombinant human factor IX produced in cultured CHO cells is nearly identical to natural, plasma-derived factor IX and is widely...

Cite
Kovnir SV, Orlova NA, Shakhparonov MI, et al. A Highly Productive CHO Cell Line Secreting Human Blood Clotting Factor IX. Acta Naturae. 2018;10(1):51-65
Kovnir, S. V., Orlova, N. A., Shakhparonov, M. I., Skryabin, K. G., Gabibov, A. G., & Vorobiev, I. I. (2018). A Highly Productive CHO Cell Line Secreting Human Blood Clotting Factor IX. Acta naturae, 10(1), 51-65.
Kovnir, S V, et al. "A Highly Productive CHO Cell Line Secreting Human Blood Clotting Factor IX." Acta naturae vol. 10,1 (2018): 51-65.
Kovnir SV, Orlova NA, Shakhparonov MI, Skryabin KG, Gabibov AG, Vorobiev II. A Highly Productive CHO Cell Line Secreting Human Blood Clotting Factor IX. Acta Naturae. 2018 Jan-Mar;10(1):51-65. PMID: 29713519; PMCID: PMC5916734.
Copy Download .nbib Format: NLM
Plasticity-related gene 3 (.

Neurology. Genetics

Wallen ZD, Chen H, Hill-Burns EM, Factor SA, Zabetian CP, Payami H.
PMID: 30338293
Neurol Genet. 2018 Oct 05;4(5):e271. doi: 10.1212/NXG.0000000000000271. eCollection 2018 Oct.

OBJECTIVE: To identify modifiers of age at diagnosis of Parkinson disease (PD).METHODS: Genome-wide association study (GWAS) included 1,950 individuals with PD from the NeuroGenetics Research Consortium (NGRC) study. Replication was conducted in the Parkinson's, Genes and Environment study, including...

Cite
Wallen ZD, Chen H, Hill-Burns EM, et al. Plasticity-related gene 3 (. Neurol Genet. 2018;4(5):e271doi: 10.1212/NXG.0000000000000271.
Wallen, Z. D., Chen, H., Hill-Burns, E. M., Factor, S. A., Zabetian, C. P., & Payami, H. (2018). Plasticity-related gene 3 (. Neurology. Genetics, 4(5), e271. https://doi.org/10.1212/NXG.0000000000000271
Wallen, Zachary D, et al. "Plasticity-related gene 3 (." Neurology. Genetics vol. 4,5 (2018): e271. doi: https://doi.org/10.1212/NXG.0000000000000271
Wallen ZD, Chen H, Hill-Burns EM, Factor SA, Zabetian CP, Payami H. Plasticity-related gene 3 (. Neurol Genet. 2018 Oct 05;4(5):e271. doi: 10.1212/NXG.0000000000000271. eCollection 2018 Oct. PMID: 30338293; PMCID: PMC6186025.
Copy Download .nbib Format: NLM
Neonatal Gene Therapy for Hemophilia B by a Novel Adenovirus Vector Showing Reduced Leaky Expression of Viral Genes.

Molecular therapy. Methods & clinical development

Iizuka S, Sakurai F, Tachibana M, Ohashi K, Mizuguchi H.
PMID: 28828393
Mol Ther Methods Clin Dev. 2017 Jul 08;6:183-193. doi: 10.1016/j.omtm.2017.07.001. eCollection 2017 Sep 15.

Gene therapy during neonatal and infant stages is a promising approach for hemophilia B, a congenital disorder caused by deficiency of blood coagulation factor IX (FIX). An adenovirus (Ad) vector has high potential for use in neonatal or infant...

Cite
Iizuka S, Sakurai F, Tachibana M, et al. Neonatal Gene Therapy for Hemophilia B by a Novel Adenovirus Vector Showing Reduced Leaky Expression of Viral Genes. Mol Ther Methods Clin Dev. 2017;6:183-193doi: 10.1016/j.omtm.2017.07.001.
Iizuka, S., Sakurai, F., Tachibana, M., Ohashi, K., & Mizuguchi, H. (2017). Neonatal Gene Therapy for Hemophilia B by a Novel Adenovirus Vector Showing Reduced Leaky Expression of Viral Genes. Molecular therapy. Methods & clinical development, 6183-193. https://doi.org/10.1016/j.omtm.2017.07.001
Iizuka, Shunsuke, et al. "Neonatal Gene Therapy for Hemophilia B by a Novel Adenovirus Vector Showing Reduced Leaky Expression of Viral Genes." Molecular therapy. Methods & clinical development vol. 6 (2017): 183-193. doi: https://doi.org/10.1016/j.omtm.2017.07.001
Iizuka S, Sakurai F, Tachibana M, Ohashi K, Mizuguchi H. Neonatal Gene Therapy for Hemophilia B by a Novel Adenovirus Vector Showing Reduced Leaky Expression of Viral Genes. Mol Ther Methods Clin Dev. 2017 Jul 08;6:183-193. doi: 10.1016/j.omtm.2017.07.001. eCollection 2017 Sep 15. PMID: 28828393; PMCID: PMC5552065.
Copy Download .nbib Format: NLM
An Immune-Competent Murine Model to Study Elimination of AAV-Transduced Hepatocytes by Capsid-Specific CD8.

Molecular therapy. Methods & clinical development

Palaschak B, Marsic D, Herzog RW, Zolotukhin S, Markusic DM.
PMID: 28480313
Mol Ther Methods Clin Dev. 2017 Apr 19;5:142-152. doi: 10.1016/j.omtm.2017.04.004. eCollection 2017 Jun 16.

Multiple independent adeno-associated virus (AAV) gene therapy clinical trials for hemophilia B, utilizing different AAV serotypes, have reported a vector dose-dependent loss of circulating factor IX (FIX) protein associated with capsid-specific CD8

Cite
Palaschak B, Marsic D, Herzog RW, et al. An Immune-Competent Murine Model to Study Elimination of AAV-Transduced Hepatocytes by Capsid-Specific CD8. Mol Ther Methods Clin Dev. 2017;5:142-152doi: 10.1016/j.omtm.2017.04.004.
Palaschak, B., Marsic, D., Herzog, R. W., Zolotukhin, S., & Markusic, D. M. (2017). An Immune-Competent Murine Model to Study Elimination of AAV-Transduced Hepatocytes by Capsid-Specific CD8. Molecular therapy. Methods & clinical development, 5142-152. https://doi.org/10.1016/j.omtm.2017.04.004
Palaschak, Brett, et al. "An Immune-Competent Murine Model to Study Elimination of AAV-Transduced Hepatocytes by Capsid-Specific CD8." Molecular therapy. Methods & clinical development vol. 5 (2017): 142-152. doi: https://doi.org/10.1016/j.omtm.2017.04.004
Palaschak B, Marsic D, Herzog RW, Zolotukhin S, Markusic DM. An Immune-Competent Murine Model to Study Elimination of AAV-Transduced Hepatocytes by Capsid-Specific CD8. Mol Ther Methods Clin Dev. 2017 Apr 19;5:142-152. doi: 10.1016/j.omtm.2017.04.004. eCollection 2017 Jun 16. PMID: 28480313; PMCID: PMC5415329.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 435 entries